Novo Nordisk nach Split WKN: A3EU6F ISIN: DK0062498333 Kürzel: NOV Forum: Aktien User: Coronaprofiteur

Geht ja nur noch seit Monaten runter. Lächerlich.

reported that its Phase 3 ZEUS study of ziltivekimab failed to reduce the risk of heart attacks, strokes, or cardiovascular death. Although the drug successfully lowered inflammation, it did not improve cardiovascular outcomes compared with placebo in patients with cardiovascular disease and chronic kidney disease. Novo Nordisk said the result will not change its 2026 operating profit outlook but will result in a non cash impairment charge in Q3. The company also confirmed that two other late stage studies of ziltivekimab in heart failure and heart attack patients will continue, with results expected in the first half of 2027.

Eher Richtung 1€

Wieder Richtung 30?

https://finance.yahoo.com/healthcare/articles/novo-nordisk-provides-zeus-phase-112100293.html

Das wird niemals hier was werden

NOVO NORDISK $NVO ZILTIVEKIMAB FAILS TO REDUCE MACERISK IN ZEUS PHASE 3 TRIAL; COMPANY SAYS OUTCOME WILL NOT IMPACT 2026 ADJUSTED OPERATING PROFIT OUTLOOK BUT WILL RESULT IN Q3 NON-CASH IMPAIRMENT CHARGE

Hab ich was verpasst

10 % Minus😥🤷‍♂️

Was jetzt los

Viel aua 😅

Aua📉

Welche Bedeutung hat das für die Quartalszahlen deiner Meinung nach?

21% wegovy zu 79% zepbound bei den spritzen ist schon krass. Das gleiche Verhältnis ist bei Wegovy Pill zu foundayo vorhanden

Novo wächst , zwar nicht so schnell wie lilly aber es wächst. Medicare zeigt 80% bevorzugen die Spritze. Wenn alles gleich viel kostet nimmt man natürlich das beste was man bekommen kann. Der Rest nimmt die pille aus Angst vor spritzen oder der einfacheren Handhabung. Novo braucht einfach eine bessere spritze um lilly da angreifen zu können.

$LLY $NVO $VKTX bofa Based on 4 weeks of Symphony data in July, total obesity TRx in Medicare (Novo+ LLY) has grown 57% (since data 3rd July). Yet, as of data for week 24th July, $LLY has c68% share of this new growth. This is because injectables represent81% of TRx growth in Medicare since start of July, &Zepbound has 79% share of the incremental injectable volume. While $NVO dominates in incremental oral capture (78% share for Wegovy pill vs 22% for Foundayo), orals are capturing a smaller portion (19%)of the Medicare expansion so far.